Overview

• Senseonics Q2 revenue grows 37% yr/yr to $6.6 mln, driven by U.S. patient growth

• Net loss narrows to $14.5 mln, aided by improved gross profit margins

• Co raises $77.8 mln to support Eversense 365 launch and pipeline development

Outlook

• Senseonics expects 2025 revenue of $34-38 mln

• Company projects 2025 gross margins of 32.5%-37.5%

• Senseonics anticipates cash use of $60 mln in 2025

• Revenue expected to be weighted to Q4 due to reorder dynamics

Result Drivers

• U.S. PATIENT GROWTH - 79% increase in new patient starts in the U.S. drives revenue growth

• DTC ADVERTISING - Expanded direct-to-consumer campaign boosts leads by 50%

• GROSS PROFIT MARGINS - Improved margins on 365-day product and one-time tax gain enhance profitability

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Senseonics Holdings Inc is $1.33, about 61.8% above its August 5 closing price of $0.51

Press Release: ID:nGNX5JVQQ8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)